Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Solid Tumor 1Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × fedratinib × Clear all
NCT01585623 2025-03-05

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Bristol-Myers Squibb

Phase 1 Completed
16 enrolled
Other solid neoplasm

Solid Tumor

NCT01836705 2025-03-05

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡